Admissions:
On Friday 6 June, File Forge Technology PLC (to be renamed Amirose London Holdings PLC), announced the completion of its acquisition of Amirose London Ltd and the Admission to trading on the Access Segment of the Aquis Stock Exchange. Amirose provides contract manufacturing services in the personal care sector for global and boutique premium brands. Turnover for the year ended 30 March 2024 was £12.7m and profits of £38.8k. Draft unaudited accounts for the year ended 30 March 2025 showed a turnover of approximately £11m and breakeven EBITDA. A total of £245k was raised on Admission by way of subscription. A further £65k has been raised by way of a placing to provide additional working capital for Amirose London Ltd's contract manufacturing services. The Company's market capitalisation on Admission was £5.87m.
Delistings:
Today, Renewi (RWI.L) left the Main Market
Potential** Initial Public Offerings:
9th May: iFOREX Financial Trading, the fintech business with a proprietary online and mobile trading platform for multi-asset contracts for difference, announces that it has confirmed its intention to IPO onto the Main Market. The Company developed and operates a proprietary online and mobile CFD trading platform, allowing primarily retail clients to trade CFDs across 870+ financial instruments, including currencies, commodities, indices, stocks, cryptocurrencies and exchange traded funds. For the year ended 31 December 2024, trading income was $50.1m, adjusted EBITDA of $9.7m and adjusted profit before tax of $7.6m. The current intention is to maintain a progressive dividend policy, and the dividend for FY2025 is expected to be set at approximately 50 per cent. of adjusted profits. Deal size TBC but timing is expected late June 2025.
Market Movers:
Updated 4 June 2025: Ajax Resources (AJAX.L) is planning to move to the Aquis Stock Exchange Growth Market Access Category from the Main Market of the London Stock Exchange. The Company expects cancellation to take place at 08:00 BST on 18 June 2025, with Admission to trading on AQSE to occur concurrently. Ajax is pursuing a strategy as a natural resources investment company, with a focus on Copper, Gold, Zinc, Uranium, and Lead. The Company completed its first acquisition on 21 May 2025. The Company’s first acquisition was the purchase of Puna Metals S.A., holding the mining rights for 12 licences, collectively forming the Eureka Gold and Copper project in the north-west corner of the Province of Jujuy in Argentina.
CAP-XX Limited 0.17p £9.24m (CPX.L)
The designer and manufacturer of thin, prismatic supercapacitors and energy management systems updates on trading for the five-months to May 2025. The first batch of its co-branded supercapacitor products have been shipped to SCHURTER Group's warehouse, which is a significant milestone in CAP-XX's strategic partnership and extends the Company's product reach into global industrial and electronics markets. Several other distribution agreements have been signed in the period, with additional agreements in negotiation. A new Interim Chief Financial Officer has been appointed, and the Company has maintained a strong cash position with cash as at end May 2025 of AU$4.2m compared to 31 January 2025 of AU$5m.
Cordel Group 7.13p £17.63m (CRDL.L)
The Artificial Intelligence (AI) platform for transport corridor analytics updates on FY June 2025 Trading. The Board currently expects to report a 12% increase in revenue to between £4.7m-£5m. Due to the economic uncertainty, particularly in the US, protracted sales cycles have impacted on the normally strong H2, so results will be lower than expectations. The breakthroughs in Multimodal AI have accelerated the acceptance of Cordel’s Positive Train Control (PTC) solution by the rail industry. The board has confidence in the revenue growth that the PTC solution this will deliver in FY206.
DigitalBox 4.30p £5.01m (DBOX.L)
The mobile-first digital media business, which owns Entertainment Daily, The Daily Mash, The Tab, The Poke, TV Guide, Emmerdale Insider, Royal Insider, and Reality Shrine announces that, further to its announcement on 14 March 2025, it has completed the acquisition of the digital assets of The Life Network from Media Chain Group Limited. The total consideration for the Acquisition was £200k, comprising the £20k license fee paid in March and a further £180k cash on completion. Under the final agreement, ownership of The Life Network's Facebook and Instagram pages has transferred to Digitalbox. The Life Network assets have been acquired to progress the development of Royal Insider. After a period of successful testing of the assets on Royal Insider, and a positive trading performance across Digitalbox's wider portfolio during H1 2025, the Board made the decision to progress with the Acquisition. The Board expects the Acquisition to be earnings enhancing in FY 2025.
First Class Metals 2.30p £4.12m (FCM.L)
The Company focused on the discovery of economic metal deposits across exploration properties in Ontario, Canada, provides an exploration update for the work conducted in 2024/25 Winter field season. Five Very Low Frequency geophysical surveys were completed across key target areas at North Hemlo, including the high-potential 'H Lake' and 'Rogers lake' zones. Strong conductors were identified, defining multiple follow-up exploration targets. The Dead Otter VLF grid launched post-winter, expanding geophysical coverage along strike of previously reported high-grade gold showings, also targeting a new gold-zone 30m from main zone. The North Hemlo tenure consolidated to 81km² following full acquisition of the OnGold claims, securing control of a strategic and highly prospective land package. The Company also updated on it Sunbeam property and Kerrs Gold project.
MediaZest 0.07p £1.1m (MDZ.L)*
The creative audio-visual solutions provider announces the appointment of Keith Edelman as Chairman of the Company with immediate effect. Keith will succeed Lance O’Neill, who has decided to retire from the Board, having been Chairman for over 18 years. Keith has over 40 years industry experience, working with FTSE 100, 250, AIM-listed and privately held companies across retail, hospitality, infrastructure, finance, sport, and digital sectors. As a former Managing Director of Arsenal FC, Keith successfully delivered the £390m Emirates Stadium project, raised over £1bn in financing, and orchestrated landmark commercial deals for the club. His vast experience also includes NED work with the likes of the London Legacy Development Corporation, Supergroup Plc, Thorntons Plc, Glenmorangie Plc and Eurotunnel. Amongst his operational roles, he was Corporate Director at Ladbroke Group Plc, Managing Director at Carlton Communications Plc, and Group Chief Executive at Storehouse Plc.
Petards Group 7.75p £4.70m (PEG.L)*
The AIM quoted developer of advanced security, communication, and surveillance systems announces that its subsidiary, QRO Solutions, has recently received an order worth almost £0.3m for ANPR systems. The order is from one of its UK police force customers, for the supply and installation of QRO's NASBox roadside ANPR systems, under a framework agreement, adding to the NASBox systems it already successfully operates in its region. The order is scheduled to be delivered and installed during the current financial year.
Prospex Energy 5.65p £21.74m (PXEN.L)
The AIM quoted investing Company focused on European gas and power projects announces that it has been advised by the Operator of the Viura field, HEYCO Energia Iberia S.L. (the operator HEI), that the workover rig to repair a leak in the completion tubing in the Viura-1B well is currently on site and operational. The Operator has also advised that the reinstatement of production from the Viura-1B well is therefore imminent. The Viura-1B well was shut during April 2025 owing to a leak in the completion tubing which required a rig intervention to reinstate production. Prospex owns 7.24% of the Viura field through its ownership of 7.5% of HEI. Prospex is accruing 14.47% of the production income from the Viura gas field until payback of its capital investment (expected to be £8m) plus the accrued 10% p.a. interest thereon.
Strategic Minerals 0.29p £6.81m (SML.L)
The international mineral exploration and production Company provided an update regarding its wholly owned subsidiaries, Leigh Creek Copper Mine Pty Ltd and Cornwall Resources Limited (CRL). Further to the Leigh Creek announcements of 24 April and 23 May 2025, the Company has received written confirmation from the Purchaser that it has secured the necessary funds and will make the payment to Strategic Minerals of A$100k for an exclusive call option to acquire 100% of the Leigh Creek Copper Mine during the week commencing 9 June 2025. The Cornwall Resources Ltd Subsidiary has separately confirmed that it has signed a drilling contract with Priority Drilling UK ltd for a fully-funded drilling programme at Redmoor as the major component of its match grant funded project. CRL is exploring for further tungsten, tin, and copper mineralisation in its Tamar Valley licence areas in east Cornwall, with a key focus on its Redmoor Project.
Synectics 327.5p £57.39m (SNX.L)
The UK-based Company which operates in advanced security and surveillance solutions provides an update on trading for the six months ended 31 May 2025. Synectics has continued to see solid order intake and ongoing new business momentum across the Group in H1 2025, with trading for the year ending 30 November 2025 comfortably in line with market expectations (revenue of £65m and adjusted PBT of £5.3m), in addition to maintaining its cash position. Company progress has been positive in the year to date, securing extensions and repeat orders with existing long-term customers across a variety of sectors and geographies, in addition to securing new customer mandates.
Tissue Regenix Group 31.50p £22.13m (TRX.L)
The regenerative medical devices Company announces that it has received CE certification under the EU Medical Device Regulation and UK Conformity Assessed certification under the UK Medical Device Regulation for OrthoPureXT, its biological tendon replacement technology. The OrthoPureXT device previously received the CE certification under the EU Medical Device Directive (MDD), but the EU MDR represents the recent improvements in standards for safety and efficacy of medical devices. This provides Tissue Regenix with uninterrupted access to the Euro 140+bn European medical device market, positioning the Company for continued revenue growth and further international expansion for OrthoPureXT.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
